While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient ...

Zentalis Pharmaceuticals, Inc.’s ZNTL share price has surged by 31.29%, which has investors questioning if this is right time to sell.

However, researchers at the Penn Ovarian Cancer Research Center at the University of Pennsylvania are studying a surprising ...

Equities research analysts at Wedbush boosted their FY2024 EPS estimates for shares of Zentalis Pharmaceuticals in a research note issued to investors on Wednesday, January 29th. Wedbush analyst R.

Ovarian cancer is the deadliest gynecologic malignancy globally and is increasing in incidence and mortality with currently ...

Ovarian cancer has seen a significant shift in its treatment paradigm with the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors, which are now standard in the maintenance setting ...

Researchers at Peter Mac have uncovered potential new heredity genes that might be responsible for causing one of the most ...

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors, which are now standard ...

To provide updated guidance regarding neoadjuvant chemotherapy (NACT) and primary cytoreductive surgery (PCS) among patients with stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal ...

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction of poly (ADP-ribose ...

High HSP60 expression in ovarian cancer is linked to poor prognosis and aggressive tumor features, including advanced FIGO stage and lymph node metastasis. Patients with elevated HSP60 levels ...